Acta Medica Okayama 72巻 5号
2018-10 発行
Kanamitsu, Kiichiro
Department of Pediatrics, Okayama University Hospital
Chayama, Kousuke
Department of Pediatrics, Toyonaka Municipal Hospital
Washio, Kana
Department of Pediatrics, Okayama University Hospital
Yoshida, Ryuichi
Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
Umeda, Yuzo
Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
Yagi, Takahito
Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
Shimada, Akira
Department of Pediatrics, Okayama University Hospital
Hepatitis-associated aplastic anemia (HAAA) is an acquired bone marrow failure syndrome that develops after seronegative fulminant hepatitis. Abnormal cytotoxic T-cell activation with cytokine release is a possible pathophysiology. We present the case of a 16-month-old Japanese male who developed HAAA following living-donor liver transplantation for fulminant hepatitis. His aplastic anemia was successfully treated with immunosuppressive therapy. He had been administered tacrolimus for prophylaxis against hepatic allograft rejection. Ten years after the HAAA onset, the patient’s bone marrow was found to be slightly hypoplastic. Tacrolimus may be effective in controlling abnormal immune reactions that can cause recurrent impaired hematopoiesis.
hepatitis-associated aplastic anemia
impaired hematopoiesis
liver transplantation
immunosuppressive therapy
abnormal immune reaction